Extensively StudiedInjectable
Semaglutide
Semaglutide (GLP-1 Receptor Agonist)
Dose
0.25-2.4mg
Frequency
1x weekly
Cycle
Ongoing
Storage
Refrigerated 2-8°C
Overview
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the incretin hormone. It has been extensively studied for its effects on glucose metabolism, appetite regulation, and cardiovascular health.
Molecular Information
Molecular Weight
4113.58 g/mol
Formula
C187H291N45O59
CAS Number
910463-68-2
Research Indications
- Obesity Management Research
- Type 2 Diabetes Studies
- Cardiovascular Risk Reduction
- Metabolic Syndrome Research
- Appetite Regulation Studies
Research Protocols
| Phase | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Titration | 0.25mg | 1x weekly | Week 1-4 | Gradual dose escalation |
| Escalation | 0.5mg | 1x weekly | Week 5-8 | Increase as tolerated |
| Maintenance | 1.0-2.4mg | 1x weekly | Ongoing | Target dose based on response |
Interactions
- May affect absorption of oral medications
- Use caution with other diabetes medications
- May enhance effects of diet interventions
How to Reconstitute
Typically supplied as pre-filled pens. If powder form, reconstitute per manufacturer instructions.
Quality Indicators
FDA Approved
Approved for medical use
Extensive Data
Large clinical trial database
GI Side Effects
Common during titration
What to Expect
1
Week 1-4: Reduced appetite, possible nausea
2
Week 4-8: Significant appetite suppression
3
Week 8-16: Notable weight reduction
4
Ongoing: Sustained metabolic benefits
Side Effects & Safety
- Nausea (especially initially)
- Diarrhea or constipation
- Injection site reactions
- Fatigue
- Rare: pancreatitis risk